1
|
Correlation between genetic polymorphisms in apolipoprotein E and atrial fibrillation. Rev Port Cardiol 2022; 41:417-423. [PMID: 36062643 DOI: 10.1016/j.repc.2021.03.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 02/27/2021] [Accepted: 03/02/2021] [Indexed: 11/22/2022] Open
Abstract
This work explores correlations between genetic polymorphisms in apolipoprotein E (ApoE) and atrial fibrillation (AF). We detected polymorphisms in the APOE gene in 64 patients with AF and 49 non-AF volunteers at the Department of Cardiology of Lianyungang Second People's Hospital between July 2017 and July 2019. We found significant differences in age, body mass index, left atrial diameter, and left ventricular ejection fraction between the two groups. Six APOE genotypes were observed: ɛ2/ɛ2; ɛ2/ɛ3; ɛ2/ɛ4; ɛ3/ɛ3; ɛ3/ɛ4; and ɛ4/ɛ4. The ɛ3/ɛ3 genotype was significantly less frequent in the AF group than in the control group, while the ɛ3/ɛ4 and ɛ4/ɛ4 genotypes were significantly more frequent in the AF group than in the control group (p<0.05). ApoE3 penetrance was significantly lower in the AF group than in the control group (p<0.05), while ApoE4 penetrance was significantly higher in the AF group than in the control group (p<0.05). ApoE3 penetrance was significantly lower in the AF group than in the control group (p<0.05). Binary logistic regression analysis showed that age, body mass index, left atrial diameter, left ventricular ejection fraction, and ApoE4 were risk factors for AF. Finally, we found that ApoE polymorphisms impacted the occurrence of AF and that ApoE4 is an AF-sensitive phenotype.
Collapse
|
2
|
Naruse Y, Keçe F, de Riva M, Watanabe M, Wijnmaalen AP, Dehnavi RA, Schalij MJ, Zeppenfeld K, Trines SA. Effect of Non-fluoroscopic Catheter Tracking on Radiation Exposure during Pulmonary Vein Isolation: Comparison of Four ablation systems. J Atr Fibrillation 2018; 11:2068. [PMID: 31139273 DOI: 10.4022/jafib.2068] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2017] [Revised: 08/19/2017] [Accepted: 09/14/2017] [Indexed: 11/10/2022]
Abstract
Background A novel non-fluoroscopic catheter tracking system (Mediguide) can be used in combination with a 3D mapping system for atrial fibrillation (AF) ablation. However, the benefit on radiation exposure of the Mediguide system compared to other ablation systems is unknown. Methods We retrospectively enrolled consecutive 73 patients (51 men; 59±11 years; 60 paroxysmal AF) undergoing pulmonary vein isolation by the same operator. Radiation time, radiation effective dose, procedure time, AF recurrence after ablation, and procedure-related complications were compared among 4 different ablation systems. Results Mediguide was used in 16 patients (group A), CARTO™ in 17 (group B), Cryoballoon in 30 (group C), and Multi-electrode Pulmonary Vein Ablation Catheter (PVAC) in 10 (group D). Although procedure time was shorter in patients with Cryoballoon (median 110 [interquartile range 99-120] min) and PVAC (123 [112-146] min) compared to those with Mediguide (181 [168-214] min) and CARTO (179 [160-195] min) (P<0.001), radiation exposure time and effective dose were decreased in patients with Mediguide compared to the other ablation systems (A: 5 [3-6] min; B: 14 [11-16] min; C: 14 [11-18] min; D: 20 [16-24] min, P<0.001 and A: 1.1 [0.8-2.0] mSv; B: 2.5 [1.3-3.8] mSv; C: 2.0 [1.4-2.5] mSv; D: 1.7 [1.4-3.6] mSv, P=0.015, respectively). AF recurrence rates and procedure-related complications were comparable among the 4 groups. Conclusion The Mediguide system reduces radiation exposure compared to other ablation systems without increasing AF recurrence or procedure-related complications.
Collapse
Affiliation(s)
- Yoshihisa Naruse
- Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Fehmi Keçe
- Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Marta de Riva
- Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Masaya Watanabe
- Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
| | | | | | - Martin J Schalij
- Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Katja Zeppenfeld
- Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Serge A Trines
- Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
| |
Collapse
|
3
|
Impact of Metabolic Status on the Course of Atrial Fibrillation. ROMANIAN JOURNAL OF DIABETES NUTRITION AND METABOLIC DISEASES 2018. [DOI: 10.2478/rjdnmd-2018-0019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Abstract
Background and aims: Metabolic syndrome (MS) might influence the course of atrial fibrillation (AF) similarly to diabetes (DM). Aim of this research is to evaluate the quality of life, disease burden and medication adherence of patients with different metabolic states. Material and methods: A cross-sectional study of Latvian Center of Cardiology Arrhythmology Department patients with AF, sorting patients in 3 categories according to the National Institutes for Health guidelines criteria for MS. Results: From 133 patients, 51 were in metabolically healthy (MH) group, 58 in MS group and 24 had DM. Average age was 62.59 in MH, 67.59 in MS and 66.25 in DM group. Most common form of AF was persistent - MH 49%, MS 65.5%, DM 75%. Best EHRA median value was observed in DM group (29.2% reporting mild symptoms). Majority of patients had 1-2 comorbidities in MH and MS group and 3-5 in the DM group, with almost all patients using 4-9 drugs daily. Conclusions: A similar course of AF was observed in MS and DM groups. Since the same molecular pathways are involved, MS should be viewed as a cluster of risk factors with a cumulative effect - greater than the effect of a single risk factor.
Collapse
|
4
|
Daimee UA, Biton Y, Aktas MK, Zannad F, Klein H, Szepietowska B, McNitt S, Polonsky B, Wang PJ, Zareba W, Moss AJ, Kutyifa V. Effect of Significant Weight Change on Inappropriate Implantable Cardioverter-Defibrillator Therapy. PACING AND CLINICAL ELECTROPHYSIOLOGY: PACE 2017; 40:9-16. [PMID: 27808410 DOI: 10.1111/pace.12973] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Revised: 09/12/2016] [Accepted: 10/11/2016] [Indexed: 11/28/2022]
Abstract
BACKGROUND Weight loss has been associated with adverse outcomes among heart failure (HF) patients, including those receiving cardiac resynchronization therapy with defibrillator (CRT-D). The effect of significant weight change on inappropriate implantable cardioverter-defibrillator (ICD) therapy among CRT-D patients is not well understood. METHODS We evaluated the impact of significant weight change at 1 year on subsequent inappropriate ICD therapy during follow-up among 993 CRT-D patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy. Patients were divided into three subgroups based on weight change at 1 year after enrollment: weight loss (weight loss ≥ 5%), weight gain (weight gain ≥ 5%), and stable weight (weight loss and weight gain < 5%). The primary end point was inappropriate ICD therapy. Secondary end point included inappropriate ICD therapy related to supraventricular arrhythmias (SVAs). RESULTS There were 102 (10.3%) patients who experienced weight loss, 689 (69.4%) whose weight was stable, and 202 (20.3%) who gained weight at 1 year. Patients with weight loss had increased risk of subsequent inappropriate ICD therapy relative to patients with stable weight (hazard ratio [HR] = 2.35, 95% confidence interval [CI]: 1.39-3.98, P = 0.001) or weight gain (HR = 2.27, 95% CI: 1.18-4.38, P = 0.014). Furthermore, patients losing weight were at greater risk of subsequent inappropriate ICD therapy related to SVAs when compared to patients with stable weight (HR = 2.16, 95% CI: 1.18-3.95, P = 0.013) or weight gain (HR = 2.02, 95% CI: 0.95-4.29, P = 0.068). CONCLUSION In mild HF patients receiving CRT-D, significant weight loss at 1 year is associated with increased risk of subsequent inappropriate ICD therapy, including risk related to SVAs.
Collapse
Affiliation(s)
- Usama A Daimee
- Heart Research Follow-up Program, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA
| | - Yitschak Biton
- Heart Research Follow-up Program, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA
| | - Mehmet K Aktas
- Heart Research Follow-up Program, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA
| | - Faiez Zannad
- Department of Cardiology, Nancy University, Université de Lorraine, Nancy, France
| | - Helmut Klein
- Heart Research Follow-up Program, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA
| | - Barbara Szepietowska
- Heart Research Follow-up Program, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA
| | - Scott McNitt
- Heart Research Follow-up Program, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA
| | - Bronislava Polonsky
- Heart Research Follow-up Program, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA
| | - Paul J Wang
- Cardiology Division, Stanford University School of Medicine, Palo Alto, California, USA
| | - Wojciech Zareba
- Heart Research Follow-up Program, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA
| | - Arthur J Moss
- Heart Research Follow-up Program, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA
| | - Valentina Kutyifa
- Heart Research Follow-up Program, Division of Cardiology, University of Rochester Medical Center, Rochester, New York, USA
| |
Collapse
|